Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
11 déc. 2023 20h15 HE
|
Harpoon Therapeutics Inc.
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure...
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
02 nov. 2023 09h15 HE
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
11 déc. 2021 09h00 HE
|
Harpoon Therapeutics
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable...
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
04 juin 2021 16h00 HE
|
Harpoon Therapeutics
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting
19 mai 2021 17h02 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced...
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
21 sept. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene...
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
27 avr. 2020 06h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
21 nov. 2019 04h00 HE
|
Harpoon Therapeutics; AbbVie Inc.
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...
Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
06 nov. 2019 19h37 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
Poseida Therapeutics Raises $142 Million in Series C Financing
22 avr. 2019 07h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...